These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31864106)

  • 1. Emerging prospects for non-medical cannabis legalisation in New Zealand: An initial view and contextualization.
    Fischer B; Bullen C
    Int J Drug Policy; 2020 Feb; 76():102632. PubMed ID: 31864106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facing the option for the legalisation of cannabis use and supply in New Zealand: An overview of relevant evidence, concepts and considerations.
    Fischer B; Daldegan-Bueno D; Boden JM
    Drug Alcohol Rev; 2020 Jul; 39(5):555-567. PubMed ID: 32436274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Zealand's 'Cannabis Legalisation and Regulation Bill': an evidence-based assessment and critique of essential regulatory components towards policy outcomes.
    Fischer B; Daldegan-Bueno D
    N Z Med J; 2020 Jul; 133(1519):103-111. PubMed ID: 32777801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing New Zealand's Cannabis Legalization and Control Bill: prospects and challenges.
    Wilkins C; Rychert M
    Addiction; 2021 Feb; 116(2):222-230. PubMed ID: 32621400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of voter support for the legalization of recreational cannabis use and supply via a national referendum.
    Wilkins C; Tremewan J; Rychert M; Atkinson Q; Fischer K; Forsyth GAL
    Int J Drug Policy; 2022 Jan; 99():103442. PubMed ID: 34560621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of select cannabis use and supply indicators pre- and post-legalization in Canada.
    Fischer B; Lee A; Robinson T; Hall W
    Subst Abuse Treat Prev Policy; 2021 Oct; 16(1):77. PubMed ID: 34620191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early-Stage Cannabis Regulatory Policy Planning Across Canada's Four Largest Provinces: A Descriptive Overview.
    Watson TM; Hyshka E; Bonato S; Rueda S
    Subst Use Misuse; 2019; 54(10):1691-1704. PubMed ID: 31076006
    [No Abstract]   [Full Text] [Related]  

  • 8. Why did New Zealand's referendum to legalise recreational cannabis fail?
    Rychert M; Wilkins C
    Drug Alcohol Rev; 2021 Sep; 40(6):877-881. PubMed ID: 33677836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Toques to Tokes: Two challenges facing nationwide legalization of cannabis in Canada.
    Bear D
    Int J Drug Policy; 2017 Apr; 42():97-101. PubMed ID: 28377052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policy influence and the legalized cannabis industry: learnings from other addictive consumption industries.
    Adams PJ; Rychert M; Wilkins C
    Addiction; 2021 Nov; 116(11):2939-2946. PubMed ID: 33739486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rejection of cannabis legalization in New Zealand: issues with the Cannabis Legalization and Control Bill or wider concerns?
    Wilkins C; Rychert M
    Addiction; 2021 Feb; 116(2):236-238. PubMed ID: 33417296
    [No Abstract]   [Full Text] [Related]  

  • 12. Cannabis legalisation: should doctors be concerned?
    Kanniah G; Kumar S
    N Z Med J; 2021 Jun; 134(1537):84-90. PubMed ID: 34239164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six policy lessons relevant to cannabis legalization.
    Shover CL; Humphreys K
    Am J Drug Alcohol Abuse; 2019; 45(6):698-706. PubMed ID: 30870053
    [No Abstract]   [Full Text] [Related]  

  • 14. A critique of cannabis legalization proposals in Canada.
    Kalant H
    Int J Drug Policy; 2016 Aug; 34():5-10. PubMed ID: 27292414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-medical cannabis in North America: an overview of regulatory approaches.
    Lancione S; Wade K; Windle SB; Filion KB; Thombs BD; Eisenberg MJ
    Public Health; 2020 Jan; 178():7-14. PubMed ID: 31600630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public opinion and medical cannabis policies: examining the role of underlying beliefs and national medical cannabis policies.
    Sznitman SR; Bretteville-Jensen AL
    Harm Reduct J; 2015 Oct; 12():46. PubMed ID: 26467203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Le marché légal du cannabis suite à sa légalisation au Canada : pistes de réflexion pour un encadrement efficace.
    Patenaude C; Brochu S; Fallu JS; Jutras-Aswad D; D'Arcy L
    Can J Public Health; 2018 Apr; 109(2):215-218. PubMed ID: 29981041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-medical cannabis use: international policies and outcomes overview. An outline for Portugal.
    Barata PC; Ferreira F; Oliveira C
    Trends Psychiatry Psychother; 2022 May; 44(Suppl 1):e20210239. PubMed ID: 34898143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Zealand's review of the Psychoactive Substances Act 2013: a missed learning opportunity ahead of the national cannabis law reform referendum?
    Rychert M; Wilkins C
    Addiction; 2019 Jun; 114(6):1129-1130. PubMed ID: 30801839
    [No Abstract]   [Full Text] [Related]  

  • 20. CANNABIS LEGALIZATION IN STATE LEGISLATURES: PUBLIC HEALTH OPPORTUNITY AND RISK.
    Orenstein DG; Glantz SA
    Marquette Law Rev; 2020; 103(4):1313-1400. PubMed ID: 34376874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.